Los Angeles Capital Management LLC Sells 27,420 Shares of Haemonetics Co. (NYSE:HAE)

Los Angeles Capital Management LLC cut its stake in shares of Haemonetics Co. (NYSE:HAE) by 51.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 25,638 shares of the medical instruments supplier’s stock after selling 27,420 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Haemonetics were worth $2,192,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in the company. Carmel Capital Partners LLC acquired a new stake in shares of Haemonetics during the third quarter worth approximately $30,000. Group One Trading L.P. acquired a new stake in Haemonetics during the 3rd quarter valued at $55,000. Parkside Financial Bank & Trust raised its position in Haemonetics by 17.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock valued at $90,000 after purchasing an additional 156 shares during the last quarter. C M Bidwell & Associates Ltd. boosted its stake in Haemonetics by 19.7% in the third quarter. C M Bidwell & Associates Ltd. now owns 2,389 shares of the medical instruments supplier’s stock worth $214,000 after purchasing an additional 393 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale grew its holdings in shares of Haemonetics by 172.8% during the third quarter. DekaBank Deutsche Girozentrale now owns 2,657 shares of the medical instruments supplier’s stock worth $239,000 after purchasing an additional 1,683 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on HAE shares. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Barrington Research reiterated an “outperform” rating and set a $105.00 target price on shares of Haemonetics in a research report on Friday, April 12th. Finally, StockNews.com lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.

Haemonetics Price Performance

Shares of HAE stock opened at $95.35 on Tuesday. The firm’s 50 day moving average price is $82.81 and its two-hundred day moving average price is $82.69. The company has a debt-to-equity ratio of 0.91, a quick ratio of 1.76 and a current ratio of 2.92. The stock has a market cap of $4.84 billion, a PE ratio of 38.76, a PEG ratio of 2.23 and a beta of 0.34. Haemonetics Co. has a 52-week low of $70.74 and a 52-week high of $96.25.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The business had revenue of $336.20 million during the quarter, compared to the consensus estimate of $320.84 million. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The firm’s revenue was up 10.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.85 earnings per share. As a group, analysts forecast that Haemonetics Co. will post 3.95 EPS for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.